{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:48:53Z","timestamp":1791388133287,"version":"4.3.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer therapy is often hampered by the disease\u2019s development of resistance to anticancer drugs. We previously showed that the autonomously upregulated product of fibroblast growth factor 13 gene (<jats:italic>FGF13<\/jats:italic>; also known as FGF homologous factor 2 (<jats:italic>FHF2<\/jats:italic>)) is responsible for the cisplatin resistance of HeLa cisR cells and that it is likely responsible for the poor prognosis of cervical cancer patients treated with cisplatin. Here we show that cloperastine and two other histamine H1 receptor antagonists selectively kill HeLa cisR cells at concentrations that little affect parental HeLa S cells. The sensitivity of HeLa cisR cells to cloperastine was abolished by knocking down <jats:italic>FGF13<\/jats:italic> expression. Cisplatin-resistant A549 cisR cells were similarly susceptible to cloperastine. H2, H3, and H4 receptor antagonists showed less or no cytotoxicity toward HeLa cisR or A549 cisR cells. These results indicate that histamine H1 receptor antagonists selectively kill cisplatin-resistant human cancer cells and suggest that this effect is exerted through a molecular mechanism involving autocrine histamine activity and high-level expression of <jats:italic>FGF13<\/jats:italic>. We think this represents a potential opportunity to utilize H1 receptor antagonists in combination with anticancer agents to treat cancers in which emergent drug-resistance is preventing effective treatment.<\/jats:p>","DOI":"10.1038\/s41598-021-81077-y","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T11:03:35Z","timestamp":1610708615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Histamine H1 receptor antagonists selectively kill cisplatin-resistant human cancer cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Nobuki","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miku","family":"Ebihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuku","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"81077_CR1","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1038\/srep02899","volume":"3","author":"T Okada","year":"2013","unstructured":"Okada, T. et al. Upregulated expression of FGF13\/FHF2 mediates resistance to platinum drugs in cervical cancer cells. Sci. Rep. 3, 2899. https:\/\/doi.org\/10.1038\/srep02899 (2013).","journal-title":"Sci. Rep."},{"key":"81077_CR2","doi-asserted-by":"publisher","first-page":"E496","DOI":"10.1073\/pnas.1614876114","volume":"114","author":"DR Bublik","year":"2017","unstructured":"Bublik, D. R. et al. Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival. Proc. Natl. Acad. Sci. U.S.A. 114, E496\u2013E505 (2017).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"81077_CR3","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1038\/oncsis.2016.88","volume":"6","author":"T Redmer","year":"2017","unstructured":"Redmer, T. et al. The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis. 6, e291. https:\/\/doi.org\/10.1038\/oncsis.2016.88 (2017).","journal-title":"Oncogenesis."},{"key":"81077_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ijc.32874","volume":"147","author":"CN Johnstone","year":"2020","unstructured":"Johnstone, C. N. et al. FGF13 promotes metastasis of triple-negative breast cancer. Int. J. Cancer. 147, 230\u2013243. https:\/\/doi.org\/10.1002\/ijc.32874 (2020).","journal-title":"Int. J. Cancer."},{"key":"81077_CR5","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1039\/C9RA09245E","volume":"10","author":"RD Jayasimha","year":"2020","unstructured":"Jayasimha, R. D., Basha, S., Kotha, P. & Katike, U. Designing, docking and molecular dynamics simulation studies of novel cloperastine analogues as anti-allergic agents: Homology modeling and active site prediction for the human histamine H1 receptor. RSC Adv. 10, 4745\u20134754 (2020).","journal-title":"RSC Adv."},{"key":"81077_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/315709","author":"V Zdravkovic","year":"2011","unstructured":"Zdravkovic, V. et al. Histamine blood concentration in ischemic heart disease patients. J. Biomed. Biotechnol. https:\/\/doi.org\/10.1155\/2011\/315709 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"81077_CR7","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/eji.200535464","volume":"36","author":"D Carlos","year":"2006","unstructured":"Carlos, D. et al. Histamine modulates mast cell degranulation through an indirect mechanism in a model IgE-mediated reaction. Eur. J. Immunol. 36, 1494\u20131503. https:\/\/doi.org\/10.1002\/eji.200535464 (2006).","journal-title":"Eur. J. Immunol."},{"key":"81077_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cytogfr.2005.02.002","volume":"16","author":"M Goldfarb","year":"2005","unstructured":"Goldfarb, M. Fibroblast growth factor homologous factors: Evolution, structure, and function. Cytokine Growth Factor Rev. 16, 215\u2013220 (2005).","journal-title":"Cytokine Growth Factor Rev."},{"key":"81077_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3892\/ijo.2016.3512","volume":"49","author":"L Zhao","year":"2016","unstructured":"Zhao, L. et al. Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells. Int. J. Oncol. 49, 99\u2013110 (2016).","journal-title":"Int. J. Oncol."},{"key":"81077_CR10","first-page":"83","volume":"7","author":"MA Catania","year":"2011","unstructured":"Catania, M. A. & Cuzzocrea, S. Pharmacological and clinical overview of cloperastine in treatment of cough. Ther. Clin. Risk Manag. 7, 83\u201392 (2011).","journal-title":"Ther. Clin. Risk Manag."},{"key":"81077_CR11","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1158\/1078-0432.CCR-05-0675","volume":"11","author":"F Cianchi","year":"2005","unstructured":"Cianchi, F. et al. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin. Cancer Res. 11, 6807 (2005).","journal-title":"Clin. Cancer Res."},{"key":"81077_CR12","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/bph.14535","volume":"177","author":"NA Massari","year":"2018","unstructured":"Massari, N. A., Nicoud, M. B. & Medina, V. A. Histamine receptors and cancer pharmacology: An update. Br. J. Pharmacol. 177, 516\u2013538 (2018).","journal-title":"Br. J. Pharmacol."},{"key":"81077_CR13","doi-asserted-by":"publisher","first-page":"49111","DOI":"10.1074\/jbc.M205520200","volume":"277","author":"J Schoorlemmer","year":"2002","unstructured":"Schoorlemmer, J. & Goldfarb, M. Fibroblast growth factor homologous factors and the islet brain-2 scaffold protein regulate activation of a stress-activated protein kinase. J. Biol. Chem. 277, 49111\u201349119 (2002).","journal-title":"J. Biol. Chem."},{"key":"81077_CR14","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.cell.2012.04.046","volume":"149","author":"QF Wu","year":"2012","unstructured":"Wu, Q. F. et al. Fibroblast growth factor 13 is a microtubule-stabilizing protein regulating neuronal polarization and migration. Cell 149, 1549\u20131564 (2012).","journal-title":"Cell"},{"key":"81077_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/molecules25081960","volume":"2020","author":"Z Erkang","year":"1960","unstructured":"Erkang, Z. et al. Apigenin inhibits histamine-inducecd cervical cancer tumor growth by regulating estrogen receptor expression. Molecules 2020, 25. https:\/\/doi.org\/10.3390\/molecules25081960 (1960).","journal-title":"Molecules"},{"key":"81077_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/onc.2017.373","volume":"37","author":"Y Otani","year":"2018","unstructured":"Otani, Y. et al. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion. Oncogene 37, 777\u2013786 (2018).","journal-title":"Oncogene"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81077-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81077-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81077-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:28:12Z","timestamp":1670034492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81077-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["81077"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-81077-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"20 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1492"}}